Phase 3 Readout~month
Phase 3 Topline: A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF VEPDEGESTRANT (ARV-471/PF-07850327) PLUS PAL
- Company
- PFIZER INC (PFE)
- Drug
- vepdegestrant
- Indication
- Breast Cancer
Other upcoming events for PFE
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monot
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Bre
Phase 3 ReadoutPhase 3 Topline: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN ME
Phase 3 ReadoutPhase 3 Topline: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEB
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab an
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.